Oblimersen sodium

奥利默森钠

Report date: 2024/07/05 11:15:10
NME

Base Information

Drug NameOblimersen sodium
Drug Alias NameAugmerosen奥利美生奥布立生奥利默森Genasense +[7
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionApoptosis regulator Bcl-2 inhibitors
TargetsApoptosis regulator Bcl-2
Therapy Area/IndicationsEsophageal adenocarcinomaSkin MelanomaSolid tumours +[46
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaCanadaUnited States +[14
CombinationsNo
Global Highest StatusDiscontinued (NDA/BLA)
Highest Status in ChinaN/A
Originator CompaniesGenta Incorporated
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsEsophageal adenocarcinomaSkin MelanomaSolid tumours +[46

Other Information

ATC CodeN/A